NCT00390884

Safety and Immunogenicity of Fluzone® Vaccine in Children Who Received 2 Doses of the 2005-2006 Fluzone Formulation.

Safety and Immunogenicity of Fluzone® Influenza Virus Vaccine (2006-2007 Formulation) Among Healthy Children Immunized in Fall 2005 With Fluzone Vaccine or Placebo

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 173 (actual)
• Sponsor: Sanofi Pasteur, a Sanofi Company · Industry
• Sex: All
• Age: 11 Months – 14 Months
• Healthy volunteers: Accepted

Summary

To compare the groups with respect to influenza immune responses following Dose 1 of Fluzone vaccine (2006-2007 formulation).

Conditions

• Influenza

Interventions

Type	Name	Description
BIOLOGICAL	Influenza Virus Vaccine, Fluzone®	0.25 mL, Intramuscular
BIOLOGICAL	Influenza Virus Vaccine, Fluzone®	0.25 mL, Intramuscular

Timeline

• Start date: 2006-10-01
• Primary completion: 2007-06-01
• Completion: 2008-09-01
• First posted: 2006-10-23
• Last updated: 2016-04-14
• Results posted: 2009-12-31

Locations

5 sites across 1 country: United States